Puri and Gold pick up on this theme and further explore the clinical utility of blocking PI3K activity in B cells, both in the context of autoimmune diseases, but also by summarizing the early clinical trials that led to accelerated approval of Idelalisib for the treatment of B cell lymphomas (8). The gene discussed is PIK3CD; the disease is autoimmune disease.